<?xml version="1.0" encoding="UTF-8"?>
<ref id="b13-ir-2019-09155">
 <label>13</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Bombardier</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Hazlewood</surname>
    <given-names>GS</given-names>
   </name>
   <name>
    <surname>Akhavan</surname>
    <given-names>P</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety</article-title>
  <source>J Rheumatol</source>
  <year>2012</year>
  <volume>39</volume>
  <fpage>1583</fpage>
  <lpage>1602</lpage>
  <pub-id pub-id-type="pmid">22707613</pub-id>
 </element-citation>
</ref>
